Trials / Conditions / Advanced Clear Cell Renal Cell Carcinoma

Advanced Clear Cell Renal Cell Carcinoma

18 registered clinical trials studyying Advanced Clear Cell Renal Cell Carcinoma — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692	City of Hope Medical Center	Phase 2
Not Yet Recruiting	Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer NCT07383441	SWOG Cancer Research Network	Phase 3
Not Yet Recruiting	VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell C NCT07510334	Mayo Clinic	Phase 2
Recruiting	Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatm NCT07128680	City of Hope Medical Center	Phase 1
Recruiting	A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma NCT07123090	Stephanie Berg	Phase 2
Recruiting	Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Rena NCT07011719	Arcus Biosciences, Inc.	Phase 3
Active Not Recruiting	177LuPSMA in Renal Cell Carcinoma NCT06964958	Dana-Farber Cancer Institute	Phase 2
Active Not Recruiting	A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Tre NCT07000149	AstraZeneca	Phase 3
Recruiting	Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma NCT07097935	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 1 / Phase 2
Not Yet Recruiting	A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC NCT06870279	RenJi Hospital	Phase 1
Recruiting	CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer NCT06399419	Osel, Inc.	Phase 1
Withdrawn	Avelumab, Palbociclib and Axitinib in Advanced RCC NCT05176288	Bradley A. McGregor, MD	Phase 2
Recruiting	Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study NCT05361720	Vanderbilt-Ingram Cancer Center	Phase 2
Unknown	A Clinical Study of 6MW3211 in Patients With Renal Cancer NCT05440045	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 2
Terminated	Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer NCT04904302	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cel NCT05012371	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546	City of Hope Medical Center	Phase 1
Terminated	Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03260504	University of Washington	Phase 1